Cover Image

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival

TO THE EDITOR: Light-chain amyloidosis (AL) is a rare systemic protein deposition disorder that belongs to the group of plasma cell dyscrasias. Approximately 10% to 22% of cases are associated with symptomatic multiple myeloma or Waldenström macroglobulinemia (WM). The disease is characterized by

Saved in:
Bibliographic Details
Main Authors: Pica, Tomas (Author) , Hegenbart, Ute (Author) , Maier, Bettina (Author) , Kimmich, Christoph (Author) , Schönland, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 2018
In: Blood
Year: 2018, Volume: 131, Issue: 3, Pages: 368-371
ISSN:1528-0020
DOI:10.1182/blood-2017-09-806463
Online Access:Verlag, Volltext: http://dx.doi.org/10.1182/blood-2017-09-806463
Verlag, Volltext: http://www.bloodjournal.org/content/131/3/368
Get full text
Author Notes:Tomas Pika, Ute Hegenbart, Pavla Flodrova, Bettina Maier, Christoph Kimmich, Stefan O. Schönland
Description
Summary:TO THE EDITOR: Light-chain amyloidosis (AL) is a rare systemic protein deposition disorder that belongs to the group of plasma cell dyscrasias. Approximately 10% to 22% of cases are associated with symptomatic multiple myeloma or Waldenström macroglobulinemia (WM). The disease is characterized by
Item Description:First edition: November 27, 2017
Gesehen am 02.10.2018
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2017-09-806463

Similar Items